We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Tadalafilis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Tadalafil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2007–2023.
Based on 5 studies
Confidence
LowBy outcome
Tadalafil has an evidence score of 3/10 — emerging evidence based on 5 indexed studies. A long-acting PDE5 inhibitor (Cialis) approved for erectile dysfunction, BPH, and pulmonary hypertension, drawing geroscience interest from large observational datasets linking PDE5-inhibitor use to lower all-cause mortality, fewer cardiovascular events, and possibly reduced Alzheimer's risk. The catch: this is association, not causation — there is no longevity RCT. A prescription drug used off-label, not a supplement. Representative study: PMID 27465053.
The commonly studied dose of Tadalafil is Off-label longevity/vascular use mirrors low approved dosing (e.g. tadalafil 2.5–5 mg once daily, the dose used for BPH/daily ED) under a clinician. Not an approved longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
MitoQ
Mostly mechanism / observationalNotable regimens that report including Tadalafil — documented, not endorsed.
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tadalafil (PDE5 inhibitor)
A long-acting PDE5 inhibitor (Cialis) approved for erectile dysfunction, BPH, and pulmonary hypertension, drawing geroscience interest from large observational datasets linking PDE5-inhibitor use to lower all-cause mortality, fewer cardiovascular events, and possibly reduced Alzheimer's risk. The catch: this is association, not causation — there is no longevity RCT. A prescription drug used off-label, not a supplement.
PDE5 inhibitors like tadalafil show consistent observational associations with lower all-cause mortality, fewer cardiovascular events, and possibly reduced dementia, plus a plausible nitric-oxide/vascular mechanism — but the data are entirely associational with strong healthy-user confounding and no longevity RCT, so the geroprotector case is suggestive but unproven.
Tadalafil is a long-acting phosphodiesterase-5 (PDE5) inhibitor — the same class as sildenafil (Viagra) — approved for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.
By blocking PDE5 it raises cyclic GMP, enhancing nitric-oxide-mediated vasodilation and improving endothelial function, with additional effects on mitochondrial signaling and inflammation that are relevant to vascular and brain aging.
Its longevity interest is almost entirely observational but striking in scale: large cohort and insurance-claims analyses have found that men who use PDE5 inhibitors have lower all-cause mortality and fewer major cardiovascular events than non-users, and several big-data studies report an association between PDE5-inhibitor use and reduced incidence of Alzheimer's disease and vascular dementia.
There is also mechanistic and small-trial work on endothelial and metabolic benefits.
The honest and important caveat is that all of this is associational: men prescribed PDE5 inhibitors differ systematically from those who are not (healthier, more active, better healthcare access — classic 'healthy-user' confounding), and no randomized trial has tested whether tadalafil extends lifespan or prevents dementia.
PDE5 inhibitors are generally well tolerated (headache, flushing, nasal congestion, indigestion), but they are dangerous combined with nitrates (severe hypotension) and need caution with alpha-blockers and certain heart conditions.
Tadalafil is a prescription drug used off-label for its proposed vascular-aging benefits; it is not a dietary supplement. The score reflects consistent but observational human signals and a plausible vascular mechanism, against the absence of any longevity RCT and clear healthy-user confounding.
Tadalafil blocks PDE5, raising cyclic GMP and prolonging nitric-oxide-mediated vasodilation — improving endothelial function.
Enhanced NO signaling improves vascular and possibly cerebral blood flow, the proposed basis for cardiovascular and dementia associations.
cGMP signaling has additional effects on mitochondrial function and inflammation relevant to tissue aging.
How Tadalafil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label longevity/vascular use mirrors low approved dosing (e.g. tadalafil 2.5–5 mg once daily, the dose used for BPH/daily ED) under a clinician. Not an approved longevity regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊Low daily-dose oral tablet | Recommended |
| 💊Sildenafil (shorter-acting PDE5 inhibitor) | Alternative |
Tadalafil's long half-life suits once-daily 'vascular' dosing.
Compare Tadalafil vs Sildenafil (Viagra) →Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Low daily dose for steady vascular effect (long half-life); never combine with nitrates.
Dose-response data unavailable. The current published research for Tadalafil does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
PDE5-inhibitor users show lower all-cause mortality and fewer cardiovascular events in observational data — confounded, not causal.
Big-data studies associate PDE5-inhibitor use with reduced Alzheimer's/vascular-dementia incidence — associational only.
Improves endothelial function and blood flow via NO/cGMP — the approved effects underlie the longevity hypothesis.
Combined with nitrates it causes severe, potentially fatal hypotension; caution with alpha-blockers.
Absolute contraindication — dangerous hypotension.
Avoid until cleared by a clinician.
Use low doses and monitor blood pressure.
Combined PDE5 inhibitor + nitrate causes severe, potentially fatal hypotension — an absolute contraindication.
Additive blood-pressure lowering — use caution and lower doses.
Raise tadalafil levels; dose reduction advised.
Tip: Vasodilatory; usually mild and transient.
Tip: Class effects; often dose-related.
Tip: Seek care; avoid nitrates; prolonged erection is a medical emergency.
Timing is flexible for Tadalafil — consistent daily use matters more than the time of day. Tadalafil is long-acting (~17.5 h half-life); the low daily dose gives steady vascular effects.
Tadalafil should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are headache / flushing, nasal congestion / indigestion / back pain, hypotension / priapism / sudden vision or hearing changes. Use caution if any of these apply to you: Concurrent nitrates (any form); Recent cardiovascular event / unstable angina; Severe hypotension.
A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints.